FGEN
Price
$5.61
Change
+$0.36 (+6.86%)
Updated
Jul 3 closing price
Capitalization
22.67M
37 days until earnings call
HALO
Price
$54.00
Change
+$0.16 (+0.30%)
Updated
Jul 3 closing price
Capitalization
6.65B
38 days until earnings call
Interact to see
Advertisement

FGEN vs HALO

Header iconFGEN vs HALO Comparison
Open Charts FGEN vs HALOBanner chart's image
FibroGen
Price$5.61
Change+$0.36 (+6.86%)
Volume$33.07K
Capitalization22.67M
Halozyme Therapeutics
Price$54.00
Change+$0.16 (+0.30%)
Volume$868.07K
Capitalization6.65B
FGEN vs HALO Comparison Chart in %
Loading...
FGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FGEN vs. HALO commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FGEN is a Hold and HALO is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (FGEN: $5.61 vs. HALO: $54.00)
Brand notoriety: FGEN and HALO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FGEN: 81% vs. HALO: 29%
Market capitalization -- FGEN: $22.67M vs. HALO: $6.65B
FGEN [@Biotechnology] is valued at $22.67M. HALO’s [@Biotechnology] market capitalization is $6.65B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FGEN’s FA Score shows that 0 FA rating(s) are green whileHALO’s FA Score has 1 green FA rating(s).

  • FGEN’s FA Score: 0 green, 5 red.
  • HALO’s FA Score: 1 green, 4 red.
According to our system of comparison, HALO is a better buy in the long-term than FGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FGEN’s TA Score shows that 5 TA indicator(s) are bullish while HALO’s TA Score has 3 bullish TA indicator(s).

  • FGEN’s TA Score: 5 bullish, 5 bearish.
  • HALO’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, both FGEN and HALO are a good buy in the short-term.

Price Growth

FGEN (@Biotechnology) experienced а +5.85% price change this week, while HALO (@Biotechnology) price change was +2.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

FGEN is expected to report earnings on Aug 11, 2025.

HALO is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HALO($6.65B) has a higher market cap than FGEN($22.7M). HALO YTD gains are higher at: 12.947 vs. FGEN (-57.620). HALO has higher annual earnings (EBITDA): 705M vs. FGEN (-110.48M). HALO has more cash in the bank: 748M vs. FGEN (1.73M). FGEN has less debt than HALO: FGEN (73.4M) vs HALO (1.51B). HALO has higher revenues than FGEN: HALO (1.08B) vs FGEN (7M).
FGENHALOFGEN / HALO
Capitalization22.7M6.65B0%
EBITDA-110.48M705M-16%
Gain YTD-57.62012.947-445%
P/E RatioN/A14.36-
Revenue7M1.08B1%
Total Cash1.73M748M0%
Total Debt73.4M1.51B5%
FUNDAMENTALS RATINGS
FGEN vs HALO: Fundamental Ratings
FGEN
HALO
OUTLOOK RATING
1..100
5552
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
10040
SMR RATING
1..100
10012
PRICE GROWTH RATING
1..100
9358
P/E GROWTH RATING
1..100
5690
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HALO's Valuation (75) in the Biotechnology industry is in the same range as FGEN (93). This means that HALO’s stock grew similarly to FGEN’s over the last 12 months.

HALO's Profit vs Risk Rating (40) in the Biotechnology industry is somewhat better than the same rating for FGEN (100). This means that HALO’s stock grew somewhat faster than FGEN’s over the last 12 months.

HALO's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for FGEN (100). This means that HALO’s stock grew significantly faster than FGEN’s over the last 12 months.

HALO's Price Growth Rating (58) in the Biotechnology industry is somewhat better than the same rating for FGEN (93). This means that HALO’s stock grew somewhat faster than FGEN’s over the last 12 months.

FGEN's P/E Growth Rating (56) in the Biotechnology industry is somewhat better than the same rating for HALO (90). This means that FGEN’s stock grew somewhat faster than HALO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FGENHALO
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
74%
Momentum
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
74%
MACD
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 4 days ago
71%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
71%
Advances
ODDS (%)
Bullish Trend 11 days ago
86%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 6 days ago
68%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
63%
View a ticker or compare two or three
Interact to see
Advertisement
FGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RAFFX46.000.48
+1.05%
American Funds AMCAP R5
BNSCX16.630.13
+0.79%
UBS US Small Cap Growth A
GSMSX36.050.21
+0.59%
Goldman Sachs Mid Cap Value Svc
LRSRX13.550.08
+0.59%
Lord Abbett Small Cap Value R3
INSLX43.41-0.10
-0.23%
Invesco International Small-Mid Com R5